Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results

P Pfeiffer; B Glimelius; S Winther; C Qvortrup; M. Yilmaz; A Berglund; K Vistisen; C  Kersten; G Liposits; H Sorbye

doi:10.1093/annonc/mdz154.014

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results

P Pfeiffer, B Glimelius, S Winther, C Qvortrup, M. Yilmaz, A Berglund, K Vistisen, C Kersten, G Liposits, H Sorbye

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	mdz154.014
Tidsskrift	Annals of Oncology
Vol/bind	30
Udgave nummer	Suppl. 4
Sider (fra-til)	iv131-iv131
Antal sider	1
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdz154.014
Status	Udgivet - 2019
Begivenhed	ESMO World Congress on Gastrointestinal Cancer 2019 - Barcelona, Spanien Varighed: 3 jul. 2019 → 6 jul. 2019 Konferencens nummer: 21 https://www.esmo.org/Conferences/ESMO-World-GI-2019

Konference

Konference	ESMO World Congress on Gastrointestinal Cancer 2019
Nummer	21
Land/Område	Spanien
By	Barcelona
Periode	03/07/2019 → 06/07/2019
Internetadresse	https://www.esmo.org/Conferences/ESMO-World-GI-2019

Adgang til dokumentet

10.1093/annonc/mdz154.014

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Pfeiffer, P., Glimelius, B., Winther, S., Qvortrup, C., Yilmaz, M., Berglund, A., Vistisen, K., Kersten, C., Liposits, G., & Sorbye, H. (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology, 30(Suppl. 4), iv131-iv131. Artikel mdz154.014. https://doi.org/10.1093/annonc/mdz154.014

@article{10495a3c9b2144d99628d03005f930b3,

title = "Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results",

author = "P Pfeiffer and B Glimelius and S Winther and C Qvortrup and M. Yilmaz and A Berglund and K Vistisen and C Kersten and G Liposits and H Sorbye",

year = "2019",

doi = "10.1093/annonc/mdz154.014",

language = "English",

volume = "30",

pages = "iv131--iv131",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl. 4",

note = "ESMO World Congress on Gastrointestinal Cancer 2019<br/>, ESMO19 ; Conference date: 03-07-2019 Through 06-07-2019",

url = "https://www.esmo.org/Conferences/ESMO-World-GI-2019",

}

Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, A, Vistisen, K, Kersten, C, Liposits, G & Sorbye, H 2019, 'Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results', Annals of Oncology, bind 30, nr. Suppl. 4, mdz154.014, s. iv131-iv131. https://doi.org/10.1093/annonc/mdz154.014

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. / Pfeiffer, P; Glimelius, B; Winther, S et al.
I: Annals of Oncology, Bind 30, Nr. Suppl. 4, mdz154.014, 2019, s. iv131-iv131.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

T2 - ESMO World Congress on Gastrointestinal Cancer 2019<br/>

AU - Pfeiffer, P

AU - Glimelius, B

AU - Winther, S

AU - Qvortrup, C

AU - Yilmaz, M.

AU - Berglund, A

AU - Vistisen, K

AU - Kersten, C

AU - Liposits, G

AU - Sorbye, H

N1 - Conference code: 21

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz154.014

DO - 10.1093/annonc/mdz154.014

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

SP - iv131-iv131

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 4

M1 - mdz154.014

Y2 - 3 July 2019 through 6 July 2019

ER -